Table. 7 Occurrence of CRISPR-cas among UTIs and DRC isolates of E. faecalis
From: Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis
CRISPR locus | Total (%) | UTI isolates (%) | DRC isolates (%) | p-value |
|---|---|---|---|---|
CRISPR1 | 15 (10.42 %) | 12 (16.00 %) | 3 (4.35 %) | 0.020 |
CRISPR2 | 77 (53.47 %) | 39 (52.00 %) | 38 (55.07 %) | 0.420 |
CRISPR3 | 27 (17.75 %) | 1 (1.33 %) | 26 (37.68 %) | < 0.001 |
CRISPR1 + CRISPR2 | 11 (7.64 %) | 8 (10.67 %) | 3 (4.35 %) | 0.133 |
CRISPR1 + CRISPR3 | 0 | 0 | 0 | – |
CRISPR2 + CRISPR3 | 16 (11.11 %) | 1 (1.33 %) | 15 (21.74 %) | < 0.001 |
CRISPR1 + CRISPR2 + CRISPR3 | 0 | 0 | 0 | – |
CRISPR1 / CRISPR2 | 82 (56.94 %) | 43 (57.33 %) | 39 (56.52 %) | 0.528 |
CRISPR1 / CRISPR3 | 42 (29.17 %) | 13 (17.33 %) | 29 (42.03 %) | 0.001 |
CRISPR2 / CRISPR3 | 88 (61.11 %) | 39 (52.00 %) | 49 (71.01 %) | 0.015 |
CRISPR1 / CRISPR2 / CRISPR3 | 92 (63.89 %) | 43 (57.33 %) | 49 (71.01 %) | 0.062 |